AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12169076 — intervention group
Group type: COMPARATOR
Intervention: Hand-scrubbing protocol
Number of subjects: 4387
Study 10869895 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/d)
Number of subjects: 294
Study 10869895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 8808415 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention program (2.5-hr, 10-week activity-based program)
Number of subjects: 35
Study 8808415 — intervention group
Group type: COMPARATOR
Intervention: Control group (administered questionnaires only)
Number of subjects: 35
Study 2062513 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Airlie House classification for diabetic retinopathy
Number of subjects: 0
Study 2062513 — intervention group
Group type: EXPERIMENTAL
Intervention: Double grading system with adjudication of disagreements
Number of subjects: 0
Study 6668531 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-sitting position
Number of subjects: 100
Study 6668531 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 100
Study 30696660 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at home (73% preference) using a combination of aerobic and resistance training (41%)
Number of subjects: 423
Study 29664801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Cancer Female Sexuality score (development and validation)
Number of subjects: 466
Study 27107810 — intervention group
Group type: EXPERIMENTAL
Intervention: Running schedule emphasizing intensity (Schedule-I)
Number of subjects: 0
Study 27107810 — intervention group
Group type: COMPARATOR
Intervention: Running schedule emphasizing volume (Schedule-V)
Number of subjects: 0
Study 25139726 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted exercise
Number of subjects: 120
Study 25139726 — intervention group
Group type: COMPARATOR
Intervention: Voluntary rate cycling
Number of subjects: 120
Study 20960028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day, Schedule 2/1) + Pemetrexed (500 mg/m2)
Number of subjects: 12
Study 20960028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg/day, continuous daily dosing) + Pemetrexed (500 mg/m2)
Number of subjects: 12
Study 19251868 — intervention group
Group type: EXPERIMENTAL
Intervention: First episode of major depression (MD)
Number of subjects: 1328
Study 19251868 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent major depression (MD)
Number of subjects: 1328
Study 19251868 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed patients
Number of subjects: 1328
Study 17490489 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg once daily for 12 weeks
Number of subjects: 120
Study 17490489 — intervention group
Group type: COMPARATOR
Intervention: Bendroflumethiazide 2.5 mg once daily for 12 weeks
Number of subjects: 120
Study 15658072 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of intranasal butorphanol (treatment B)
Number of subjects: 24
Study 15658072 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of intranasal butorphanol (treatment C)
Number of subjects: 24
Study 15658072 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of i.v. butorphanol (treatment A)
Number of subjects: 24
Study 15658072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal butorphanol (1 mg and 2 mg)
Number of subjects: 24
Study 15658072 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (1 mg, 2 mg intranasal, and 2 mg i.v.)
Number of subjects: 24
Study 15658072 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 24
Study 11055460 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg per dose)
Number of subjects: 13
Study 11055460 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg per dose)
Number of subjects: 13
Study 11055460 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg and 0.6 mg/kg)
Number of subjects: 13
Study 11055460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9135403 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate 4% (DSCG)
Number of subjects: 30
Study 9135403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1%
Number of subjects: 30
Study 8398318 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 100 mg orally days 1‐14, methotrexate 50 mg i.v. days 1 and 8, 5‐fluorouracil 1 g i.v. days 1 and 8, repeating at 28‐day intervals for six courses)
Number of subjects: 84
Study 8398318 — intervention group
Group type: EXPERIMENTAL
Intervention: MMM (mitozantrone 8 mg/m2 i.v. once every 3 weeks, methotrexate 50 mg i.v. once every 3 weeks, mitomycin C 8 mg/m2 once every 6 weeks, for 8 courses)
Number of subjects: 84
Study 8398318 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional FEC (5‐fluorouracil 200 mg/m2 i.v. 24 hourly by continuous infusion for 6 months, epirubicin 50 mg/m2 i.v. bolus once every 3 weeks for 6 months, cisplatin 60 mg/m2 i.v. once every 3 weeks for 6 months)
Number of subjects: 84
Study 2946552 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel plus EE
Number of subjects: 34
Study 2946552 — intervention group
Group type: COMPARATOR
Intervention: Triphasic levonorgestrel plus EE
Number of subjects: 34
Study 3131943 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg mitomycin C (MMC) instilled for 0.5 hours
Number of subjects: 31
Study 3131943 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg mitomycin C (MMC) instilled for 1.0 hours
Number of subjects: 31
Study 3131943 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg mitomycin C (MMC) instilled for both 0.5 and 1.0 hours
Number of subjects: 31
Study 30548528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PR-A in endometrial glands
Number of subjects: 135
Study 30548528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PR-A in stroma
Number of subjects: 135
Study 30548528 — intervention group
Group type: EXPERIMENTAL
Intervention: High PR-B in endometrial glands
Number of subjects: 135
Study 30548528 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-A:PR-B ratio ≤ 1
Number of subjects: 135
Study 29136032 — intervention group
Group type: EXPERIMENTAL
Intervention: 2NRTI+NNRTI long-term ART with CD4 monitoring
Number of subjects: 1206
Study 29136032 — intervention group
Group type: COMPARATOR
Intervention: 2NRTI+NNRTI long-term ART without CD4 monitoring
Number of subjects: 1206
Study 29136032 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with VL rebound ≥5,000 copies/ml
Number of subjects: 1206
Study 29136032 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with VL 1,000-5,000 copies/ml
Number of subjects: 1206
Study 29136032 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI resistance
Number of subjects: 1206
Study 29136032 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study findings
Number of subjects: 1206
Study 25176942 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS ON)
Number of subjects: 96
Study 25176942 — intervention group
Group type: COMPARATOR
Intervention: Control (VNS OFF)
Number of subjects: 96
Study 23238489 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 15
Study 23238489 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face assessment
Number of subjects: 15
Study 21986346 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session manual-based, educator-led structured group intervention with cognitive behavioral strategies
Number of subjects: 222
Study 21986346 — intervention group
Group type: COMPARATOR
Intervention: Educator-led attention control group education program
Number of subjects: 222
Study 21986346 — intervention group
Group type: COMPARATOR
Intervention: Unlimited individual nurse and dietitian education sessions for 6 months
Number of subjects: 222
Study 17961560 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg/day E(2) patch, oral medroxyprogesterone acetate 10 mg for 12 days each month for patients
Number of subjects: 143
Study 17961560 — intervention group
Group type: COMPARATOR
Intervention: Control group (regularly menstruating women)
Number of subjects: 143
Study 17961560 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with testosterone levels below normal
Number of subjects: 143
Study 17961560 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with primary ovarian insufficiency
Number of subjects: 143
Study 16930358 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg/day
Number of subjects: 0
Study 16930358 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 2000 mg/day
Number of subjects: 0
Study 16930358 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day
Number of subjects: 0
Study 16930358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17129331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioners (NPs) as consultants performing basic incontinence evaluation and treatment for 16 weeks
Number of subjects: 320
Study 17129331 — intervention group
Group type: COMPARATOR
Intervention: Nurse practitioners (NPs) as consultants performing basic incontinence evaluation and treatment
Number of subjects: 320
Study 10654503 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization with normothermic cardiopulmonary bypass
Number of subjects: 52
Study 10654503 — intervention group
Group type: COMPARATOR
Intervention: Coronary revascularization without normothermic cardiopulmonary bypass
Number of subjects: 52
Study 9062610 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 0.15 mg/kg
Number of subjects: 30
Study 9062610 — intervention group
Group type: COMPARATOR
Intervention: saline 0.03 ml/mg
Number of subjects: 30
Study 8356168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine mesylate (DHE)
Number of subjects: 12
Study 8356168 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline (PPF)
Number of subjects: 12
Study 8356168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride maleate (LIS)
Number of subjects: 12
Study 8356168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (IDL)
Number of subjects: 12
Study 8356168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (NCG)
Number of subjects: 12
Study 8356168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3746952 — intervention group
Group type: EXPERIMENTAL
Intervention: MAST (163 patients)
Number of subjects: 352
Study 3746952 — intervention group
Group type: COMPARATOR
Intervention: No-MAST (189 patients)
Number of subjects: 352
Study 31194979 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive monitoring (trough concentrations measured at weeks 4 and 8 and then every 8 weeks until week 72, n = 38)
Number of subjects: 78
Study 31194979 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive monitoring
Number of subjects: 78
Study 31194979 — intervention group
Group type: COMPARATOR
Intervention: Reactive monitoring (physicians informed of trough concentrations after loss of response, n = 40)
Number of subjects: 78
Study 31194979 — intervention group
Group type: COMPARATOR
Intervention: Reactive monitoring
Number of subjects: 78
Study 26924839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 30
Study 26924839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26598458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 1000
Study 26598458 — intervention group
Group type: EXPERIMENTAL
Intervention: sIgE measurements for cow's milk, egg white, peanut, wheat, seafood mix, and soybean
Number of subjects: 1000
Study 23650892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ipsilateral head rotation to >30° left position
Number of subjects: 40
Study 23650892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ipsilateral head rotation to <30° right position
Number of subjects: 40
Study 20608995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin at 10 mg/day (PRAVA, n = 12)
Number of subjects: 50
Study 20608995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin at 2.5 mg/day (ROSUVA, n = 11)
Number of subjects: 50
Study 20608995 — intervention group
Group type: COMPARATOR
Intervention: Non-statin group (n = 13)
Number of subjects: 50
Study 20608995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin and VHD
Number of subjects: 50
Study 20608995 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin and Non-statin
Number of subjects: 50
Study 18270387 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading of anterior knee laxity by certified athletic trainers
Number of subjects: 12
Study 18270387 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented measurements of anterior tibial translation using MEDmetric KT1000 knee ligament Arthrometer
Number of subjects: 12
Study 16569825 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin monotherapy
Number of subjects: 266
Study 16569825 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin alone or combined with ceftriaxone
Number of subjects: 266
Study 16569825 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin with ceftriaxone
Number of subjects: 266
Study 14504894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cataract operation
Number of subjects: 116
Study 14504894 — intervention group
Group type: COMPARATOR
Intervention: No simultaneous operation (control)
Number of subjects: 116
Study 14504894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combined cataract operation and no simultaneous operation)
Number of subjects: 116
Study 11207516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg), clarithromycin (250 mg), metronidazole (400 mg) given twice daily for 1 week
Number of subjects: 180
Study 11207516 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg), clarithromycin (250 mg), metronidazole (400 mg) given twice daily for 1 week
Number of subjects: 180
Study 9049575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 30 micrograms.kg‐1.min‐1 (group I)
Number of subjects: 0
Study 9049575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 5 micrograms.kg‐1.min‐1 (group II)
Number of subjects: 0
Study 9049575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 2 micrograms.kg‐1.min‐1 (group III)
Number of subjects: 0
Study 8103646 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 12
Study 8103646 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms
Number of subjects: 12
Study 8103646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2873396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin 7.5 mg/kg per day
Number of subjects: 122
Study 2873396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 31910992 — intervention group
Group type: COMPARATOR
Intervention: Lower target glycemic control (80-100 mg/dL)
Number of subjects: 214
Study 31910992 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher target glycemic control (150-180 mg/dL)
Number of subjects: 214
Study 28455159 — intervention group
Group type: EXPERIMENTAL
Intervention: cSEMSs (fully covered self-expandable metal stents) for 6 months
Number of subjects: 64
Study 28455159 — intervention group
Group type: COMPARATOR
Intervention: MPSs (multiple plastic stents) exchanged every 3 months over 1 year
Number of subjects: 64
Study 28455159 — intervention group
Group type: EXPERIMENTAL
Intervention: cSEMSs
Number of subjects: 64
Study 28455159 — intervention group
Group type: COMPARATOR
Intervention: MPSs
Number of subjects: 64
Study 28232046 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 499
Study 28232046 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 499
Study 26825666 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsule containing four bacterial strains
Number of subjects: 64
Study 26825666 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 64
Study 23742669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 66
Study 23742669 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 66
Study 23742669 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 66
Study 21959480 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (40 mg/kg) plus diclofenac (1 mg/kg)
Number of subjects: 120
Study 21959480 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (40 mg/kg)
Number of subjects: 120
Study 21959480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (1 mg/kg)
Number of subjects: 120
Study 21959480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 18240925 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) + physical therapy (PT)
Number of subjects: 54
Study 18240925 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT) alone
Number of subjects: 54
Study 17361530 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with combination of acupuncture (HANS) and enflurane
Number of subjects: 60
Study 17361530 — intervention group
Group type: COMPARATOR
Intervention: Enflurane alone
Number of subjects: 60
Study 14663804 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl glue and minimal number of interrupted resorbable sutures
Number of subjects: 30
Study 14663804 — intervention group
Group type: COMPARATOR
Intervention: Control group (gelatin sponge and multiple interrupted resorbable sutures)
Number of subjects: 30
Study 14663804 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (patients who had never been on anticoagulant therapy)
Number of subjects: 30
Study 10822433 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic training (at least 25 hours)
Number of subjects: 56
Study 10822433 — intervention group
Group type: COMPARATOR
Intervention: Exposure to the robotic device without training
Number of subjects: 56
Study 8877668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinses containing salifluor
Number of subjects: 10
Study 8877668 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% salifluor mouthrinse
Number of subjects: 10
Study 8877668 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 10
Study 1649005 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3% pyrophosphate/1,100 ppm F/1.5% Gantrez dentifrice
Number of subjects: 15
Study 1649005 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100‐ppm F dentifrice without pyrophosphate or Gantrez
Number of subjects: 15
Study 1649005 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 15
Study 1649005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrices (both types)
Number of subjects: 15
Study 6137980 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium (group B)
Number of subjects: 52
Study 6137980 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium (group D)
Number of subjects: 52
Study 6137980 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium (group A)
Number of subjects: 52
Study 6137980 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium (group C)
Number of subjects: 52
Study 6137980 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium
Number of subjects: 52
Study 6137980 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium
Number of subjects: 52
Study 31899372 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health community health worker (CHW) intervention delivered in four visits over one year
Number of subjects: 420
Study 31899372 — intervention group
Group type: COMPARATOR
Intervention: Usual services (wait-list control)
Number of subjects: 420
Study 31430830 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 54
Study 31430830 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 54
Study 28174351 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic soy milk containing Lactobacillus plantarum A7
Number of subjects: 44
Study 28174351 — intervention group
Group type: COMPARATOR
Intervention: Conventional soy milk
Number of subjects: 44
Study 26075381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 135
Study 26075381 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Number of subjects: 135
Study 26075381 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 135
Study 26075381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and Acceptance and commitment therapy (ACT)
Number of subjects: 135
Study 23562184 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning blue-light exposure (λmax=470 nm)
Number of subjects: 21
Study 23562184 — intervention group
Group type: COMPARATOR
Intervention: Morning dim-light exposure
Number of subjects: 21
Study 21968863 — intervention group
Group type: EXPERIMENTAL
Intervention: Souvenaid (medical food)
Number of subjects: 0
Study 21968863 — intervention group
Group type: COMPARATOR
Intervention: Iso-caloric control product
Number of subjects: 0
Study 19066607 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin (arm A)
Number of subjects: 92
Study 19066607 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/vinorelbine (arm B)
Number of subjects: 92
Study 17287679 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting phosphorylcholine polymer-coated stent (n=598)
Number of subjects: 1197
Study 14749563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.1 mg/kg by mouth twice daily)
Number of subjects: 35
Study 14749563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11273789 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg orally, twice daily)
Number of subjects: 8
Study 11273789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8